JPH09509674A - 舌下又はバッカル医薬組成物 - Google Patents
舌下又はバッカル医薬組成物Info
- Publication number
- JPH09509674A JPH09509674A JP7522703A JP52270395A JPH09509674A JP H09509674 A JPH09509674 A JP H09509674A JP 7522703 A JP7522703 A JP 7522703A JP 52270395 A JP52270395 A JP 52270395A JP H09509674 A JPH09509674 A JP H09509674A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sublingual
- tetrahydro
- methyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 108010010803 Gelatin Proteins 0.000 claims description 13
- 229920000159 gelatin Polymers 0.000 claims description 13
- 239000008273 gelatin Substances 0.000 claims description 13
- 235000019322 gelatine Nutrition 0.000 claims description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims description 13
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000012876 carrier material Substances 0.000 claims description 10
- VSWBSWWIRNCQIJ-HUUCEWRRSA-N (S,S)-asenapine Chemical compound O1C2=CC=CC=C2[C@H]2CN(C)C[C@@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-HUUCEWRRSA-N 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 201000000980 schizophrenia Diseases 0.000 abstract description 4
- 208000028017 Psychotic disease Diseases 0.000 abstract description 3
- GMDCDXMAFMEDAG-CHHFXETESA-N (S,S)-asenapine maleate Chemical compound OC(=O)\C=C/C(O)=O.O1C2=CC=CC=C2[C@H]2CN(C)C[C@@H]2C2=CC(Cl)=CC=C21 GMDCDXMAFMEDAG-CHHFXETESA-N 0.000 description 19
- 229960005245 asenapine Drugs 0.000 description 19
- 239000002552 dosage form Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- VSWBSWWIRNCQIJ-UHFFFAOYSA-N 5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole Chemical compound O1C2=CC=CC=C2C2CN(C)CC2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-UHFFFAOYSA-N 0.000 description 4
- GMDCDXMAFMEDAG-BTJKTKAUSA-N db06216 Chemical compound OC(=O)\C=C/C(O)=O.O1C2=CC=CC=C2C2CN(C)CC2C2=CC(Cl)=CC=C21 GMDCDXMAFMEDAG-BTJKTKAUSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- NALWAKMXVXNWCO-BTJKTKAUSA-N (z)-but-2-enedioic acid;1h-pyrrole Chemical compound C=1C=CNC=1.OC(=O)\C=C/C(O)=O NALWAKMXVXNWCO-BTJKTKAUSA-N 0.000 description 3
- 206010031127 Orthostatic hypotension Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003420 antiserotonin agent Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000000794 anti-serotonin Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000003965 capillary gas chromatography Methods 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- DRRDYPWDPCULPC-UHFFFAOYSA-N 13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),2(6),3,7,9,11,14,16-octaene Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C2=C1CN=C2 DRRDYPWDPCULPC-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 108091008698 baroreceptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001774 pressoreceptor Anatomy 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.舌下又はバッカル医薬組成物であって、トランス−5−クロロ−2−メチル −2,3,3a,12b−テトラヒドロ−1H−ジベンズ[2,3:6,7]オ キセピノ[4,5−c]ピロール又はその医薬上許容し得る塩、及び前記組成物 における使用に適した医薬上許容し得る助剤を含むことを特徴とする医薬組成物 。 2.前記組成物が、医薬上許容し得る水溶性又は水分散性担体材料をさらに含む 、請求項1に記載の医薬組成物。 3.前記担体材料が部分加水分解ゼラチンである、請求項2に記載の医薬組成物 。 4.精神障害治療用の舌下又はバッカル医薬組成物を製造するためのトランス− 5−クロロ−2−メチル−2,3,3a,12b−テトラヒドロ−1H−ジベン ズ[2,3:6,7]オキセピノ[4,5−c]ピロールの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT94200521.6 | 1994-03-02 | ||
EP94200521 | 1994-03-02 | ||
PCT/EP1995/000765 WO1995023600A1 (en) | 1994-03-02 | 1995-03-01 | Sublingual or buccal pharmaceutical composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006217762A Division JP4616810B2 (ja) | 1994-03-02 | 2006-08-10 | 舌下又はバッカル医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09509674A true JPH09509674A (ja) | 1997-09-30 |
JP4099224B2 JP4099224B2 (ja) | 2008-06-11 |
Family
ID=8216678
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52270395A Expired - Lifetime JP4099224B2 (ja) | 1994-03-02 | 1995-03-01 | 舌下又はバッカル医薬組成物 |
JP2006217762A Expired - Lifetime JP4616810B2 (ja) | 1994-03-02 | 2006-08-10 | 舌下又はバッカル医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006217762A Expired - Lifetime JP4616810B2 (ja) | 1994-03-02 | 2006-08-10 | 舌下又はバッカル医薬組成物 |
Country Status (23)
Country | Link |
---|---|
US (1) | US5763476A (ja) |
EP (1) | EP0746317B1 (ja) |
JP (2) | JP4099224B2 (ja) |
KR (1) | KR100330942B1 (ja) |
CN (1) | CN1079670C (ja) |
AT (1) | ATE167057T1 (ja) |
AU (1) | AU692530B2 (ja) |
BR (2) | BR9506924A (ja) |
CA (1) | CA2182981C (ja) |
CZ (1) | CZ284633B6 (ja) |
DE (2) | DE69502939T2 (ja) |
DK (1) | DK0746317T3 (ja) |
ES (1) | ES2118584T3 (ja) |
FI (1) | FI117923B (ja) |
FR (1) | FR10C0056I2 (ja) |
HK (1) | HK1008417A1 (ja) |
HU (1) | HU225051B1 (ja) |
LU (1) | LU91751I2 (ja) |
NO (2) | NO308772B1 (ja) |
NZ (1) | NZ282394A (ja) |
PL (1) | PL180465B1 (ja) |
RU (1) | RU2139051C1 (ja) |
WO (1) | WO1995023600A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527238A (ja) * | 2003-06-12 | 2006-11-30 | オルガノン・アイルランド・リミテツド | 過剰体重又は過剰体重に対する素因を有する患者の統合失調症を治療するためのアセナピン |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032108A1 (en) * | 1997-12-19 | 1999-07-01 | Akzo Nobel N.V. | Org-5222 in the treatment of depression |
ATE516799T1 (de) * | 2002-02-13 | 2011-08-15 | Michael K Weibel | Arzneimitteldosenform und -herstellungsverfahren |
US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7306812B2 (en) | 2003-05-09 | 2007-12-11 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
EP1633400A2 (en) * | 2003-05-16 | 2006-03-15 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
WO2005107808A2 (en) * | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
GB0416861D0 (en) * | 2004-07-29 | 2004-09-01 | Quadrant Drug Delivery Ltd | Composition |
US20060084692A1 (en) * | 2004-10-15 | 2006-04-20 | Pfizer Inc. | Treatment of bipolar disorders and associated symptoms |
CA2603509C (en) * | 2005-04-07 | 2013-12-03 | N.V. Organon | Crystal form of asenapine maleate |
RS51341B (en) | 2005-04-07 | 2011-02-28 | N.V. Organon | INTERMEDIATE COMPOUNDS FOR THE TRANS-5-CHLOR-2-METHYL-2,3A, 12B-TETRAHYDRO-1H-DIBENZE [2,3; 6,7] OXEPINO [4,5-C] Pyrrole |
US7872147B2 (en) | 2005-04-07 | 2011-01-18 | N. V. Organon | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole |
US7741358B2 (en) * | 2005-04-14 | 2010-06-22 | N.V. Organon | Crystal form of asenapine maleate |
US7750167B2 (en) | 2006-07-05 | 2010-07-06 | N.V. Organon | Process for the preparation of asenapine and intermediate products used in said process |
US7875729B2 (en) | 2007-01-05 | 2011-01-25 | Synthon Bv | Process for making asenapine |
PE20091156A1 (es) * | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
WO2009156889A1 (en) * | 2008-06-25 | 2009-12-30 | Pfizer Inc. | Diaryl compounds and uses thereof |
WO2010127674A1 (en) * | 2009-05-06 | 2010-11-11 | Sunin K/S | Transdermal compositions of asenapine for the treatment of psychiatric disorders |
US8658687B2 (en) | 2009-06-24 | 2014-02-25 | Merck Sharp & Dohme Corp. | Injectable formulations containing asenapine and method of treatment using same |
TW201118102A (en) | 2009-07-29 | 2011-06-01 | Organon Nv | Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same |
US8779161B2 (en) | 2010-06-18 | 2014-07-15 | Dr. Reddy's Laboratories Limited | Asenapine maleate |
JP5815702B2 (ja) | 2010-07-29 | 2015-11-17 | ラボラトリオス レスヴィ,エス.エル. | アセナピンの新規な製造方法 |
WO2012038975A2 (en) * | 2010-09-22 | 2012-03-29 | Msn Laboratories Limited | Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof |
EA027840B1 (ru) | 2010-11-15 | 2017-09-29 | Эйджинбайо, Инк. | Производные пиридазина, композиции и способы лечения когнитивного нарушения |
WO2012066565A2 (en) | 2010-11-16 | 2012-05-24 | Cadila Healthcare Limited | Asenapine maleate amorphous and crystalline form and process for preparation thereof |
EP2468750A1 (en) | 2010-12-13 | 2012-06-27 | Chemo Ibérica, S.A. | Polymorphic forms of asenapine maleate and processes for their preparation |
WO2012123325A1 (en) | 2011-03-11 | 2012-09-20 | Medichem S.A. | NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID |
EP2524919A1 (en) | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids |
JP6014656B2 (ja) | 2011-05-18 | 2016-10-25 | ラビラトリオス レスビ エス エレ | 化合物の多形体 |
EP2709615A1 (en) | 2011-05-18 | 2014-03-26 | Laboratorios Lesvi, S.L. | Monoclinic crystalline form of asenapine maleate with a specific particle size distribution |
EP2572703A1 (en) | 2011-09-21 | 2013-03-27 | Hexal AG | Compressed oral dosage form for asenapine maleate |
WO2013041604A1 (en) | 2011-09-21 | 2013-03-28 | Sandoz Ag | Crystal form of asenapine maleate |
CN102657635B (zh) * | 2012-05-04 | 2013-08-07 | 上海现代药物制剂工程研究中心有限公司 | 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法 |
ITMI20121810A1 (it) | 2012-10-24 | 2014-04-25 | Chemo Iberica Sa | Poliformi di maleato di asenapina e processo per la loro preparazione |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2014090386A1 (en) | 2012-12-11 | 2014-06-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Orally disintegrating tablet containing asenapine |
CA2895534C (en) | 2012-12-20 | 2019-10-22 | Kashiv Pharma, Llc | Orally disintegrating tablet formulation for enhanced bioavailability |
CN103893139B (zh) * | 2012-12-28 | 2018-06-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种阿塞那平组合物及其制备方法 |
CN103120688A (zh) * | 2013-01-11 | 2013-05-29 | 盛世泰科生物医药技术(苏州)有限公司 | 一种闪释制剂的药物组合 |
US9545376B2 (en) | 2013-01-23 | 2017-01-17 | Arx, Llc | Production of unit dose constructs |
WO2014127786A1 (en) | 2013-02-22 | 2014-08-28 | Zentiva, K.S. | Orally disintegrating pharmaceutical composition comprising asenapine |
IN2013MU02206A (ja) * | 2013-06-28 | 2015-06-12 | Alembic Pharmaceuticals Ltd | |
CA3123897C (en) | 2013-12-20 | 2024-02-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
US20170007537A1 (en) * | 2014-02-18 | 2017-01-12 | Hetero Research Foundation | Pharmaceutical compositions of asenapine |
RU2020123764A (ru) | 2014-04-04 | 2020-08-05 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
TR201509009A1 (en) * | 2014-12-11 | 2017-02-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | THIN FILM STRIP OF ASENAPINE |
CA2987081C (en) | 2015-06-11 | 2022-08-30 | Alrise Biosystems Gmbh | Process for the preparation of drug loaded microparticles |
MX2020013374A (es) | 2015-06-19 | 2022-05-06 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo. |
JP6995761B2 (ja) | 2016-01-26 | 2022-01-17 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
JP6686168B2 (ja) | 2016-03-25 | 2020-04-22 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
US10085971B2 (en) | 2016-08-22 | 2018-10-02 | Navinta Iii Inc | Pharmaceutical solution of asenapine for sublingual or buccal use |
US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
US20180193283A1 (en) | 2016-12-20 | 2018-07-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
JP7149287B2 (ja) | 2016-12-20 | 2022-10-06 | エルテーエス ローマン テラピー-ジステーメ アーゲー | アセナピンおよびポリシロキサンまたはポリイソブチレンを含有する経皮治療システム |
US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
KR102398194B1 (ko) | 2017-03-24 | 2022-05-18 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 조성물 및 방법 |
JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
EP3765021A4 (en) | 2018-03-16 | 2022-03-09 | Intra-Cellular Therapies, Inc. | NOVEL PROCESSES |
WO2019246300A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
WO2020047408A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
CA3108553A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
MX2022000143A (es) | 2019-07-07 | 2022-02-17 | Intra Cellular Therapies Inc | Metodos novedosos. |
US20240132513A1 (en) | 2022-08-19 | 2024-04-25 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7605526A (nl) * | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
IE45770B1 (en) * | 1976-10-06 | 1982-11-17 | Wyeth John & Brother Ltd | Pharmaceutical dosage forms |
FR2480283A1 (fr) * | 1980-04-10 | 1981-10-16 | Science Union & Cie | Nouveaux derives tricycliques, leurs procedes de preparation et leur utilisation comme medicament |
JPS5967218A (ja) * | 1982-10-07 | 1984-04-16 | Grelan Pharmaceut Co Ltd | 軟質な口腔製剤 |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
CA2027243A1 (en) * | 1989-10-17 | 1991-04-18 | Everett H. Ellinwood, Jr. | Intraoral formulated trifluorobenzodiazepines and the use thereof |
EP0578823B1 (en) * | 1991-04-08 | 2002-01-23 | Sumitomo Pharmaceuticals Company, Limited | Porous solid preparation containing physiologically active protein substance |
ZA933134B (en) * | 1992-05-08 | 1993-11-30 | Akzo Nv | Depot preparation |
EP0569096A1 (en) * | 1992-05-08 | 1993-11-10 | Akzo Nobel N.V. | Depot preparation |
-
1995
- 1995-03-01 EP EP95912188A patent/EP0746317B1/en not_active Expired - Lifetime
- 1995-03-01 JP JP52270395A patent/JP4099224B2/ja not_active Expired - Lifetime
- 1995-03-01 US US08/693,064 patent/US5763476A/en not_active Expired - Lifetime
- 1995-03-01 NZ NZ282394A patent/NZ282394A/en not_active IP Right Cessation
- 1995-03-01 PL PL95316080A patent/PL180465B1/pl unknown
- 1995-03-01 WO PCT/EP1995/000765 patent/WO1995023600A1/en active IP Right Grant
- 1995-03-01 CA CA002182981A patent/CA2182981C/en not_active Expired - Lifetime
- 1995-03-01 DK DK95912188T patent/DK0746317T3/da active
- 1995-03-01 HU HU9602383A patent/HU225051B1/hu active Protection Beyond IP Right Term
- 1995-03-01 ES ES95912188T patent/ES2118584T3/es not_active Expired - Lifetime
- 1995-03-01 CN CN95191906A patent/CN1079670C/zh not_active Expired - Lifetime
- 1995-03-01 AU AU19478/95A patent/AU692530B2/en not_active Expired
- 1995-03-01 KR KR1019960704774A patent/KR100330942B1/ko not_active IP Right Cessation
- 1995-03-01 RU RU96120090/14A patent/RU2139051C1/ru active Protection Beyond IP Right Term
- 1995-03-01 AT AT95912188T patent/ATE167057T1/de active
- 1995-03-01 DE DE69502939T patent/DE69502939T2/de not_active Expired - Lifetime
- 1995-03-01 CZ CZ962541A patent/CZ284633B6/cs not_active IP Right Cessation
- 1995-03-01 BR BR9506924A patent/BR9506924A/pt not_active Application Discontinuation
- 1995-03-01 DE DE201012000050 patent/DE122010000050I2/de active Active
-
1996
- 1996-08-30 FI FI963398A patent/FI117923B/fi not_active IP Right Cessation
- 1996-08-30 NO NO19963639A patent/NO308772B1/no not_active IP Right Cessation
-
1997
- 1997-05-13 BR BR1100625-0A patent/BR1100625A/pt active IP Right Grant
-
1998
- 1998-07-14 HK HK98109126A patent/HK1008417A1/xx not_active IP Right Cessation
-
2006
- 2006-08-10 JP JP2006217762A patent/JP4616810B2/ja not_active Expired - Lifetime
-
2010
- 2010-11-04 LU LU91751C patent/LU91751I2/fr unknown
- 2010-12-13 NO NO2010024C patent/NO2010024I2/no unknown
- 2010-12-23 FR FR10C0056C patent/FR10C0056I2/fr active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527238A (ja) * | 2003-06-12 | 2006-11-30 | オルガノン・アイルランド・リミテツド | 過剰体重又は過剰体重に対する素因を有する患者の統合失調症を治療するためのアセナピン |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4099224B2 (ja) | 舌下又はバッカル医薬組成物 | |
US20020002172A1 (en) | Pharmaceutical formulations | |
JP4948691B2 (ja) | 舌下又は頬投与によって送達される薬物の徐放 | |
EP1246668B1 (en) | An rapid acting freeze dired oral pharmaceutical composition for treating migraine | |
AU2007287549B2 (en) | Galenic formulations of aliskiren | |
EP3505161B1 (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
JPH0812575A (ja) | 口腔乾燥症治療剤 | |
TWI343262B (en) | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist | |
MXPA96003713A (en) | Sublingual pharmaceutical composition or bu | |
CN110693882A (zh) | 一种舌下用药物组合物 | |
WO2005016315A1 (en) | Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler | |
US20210052608A1 (en) | Methods of treating bacterial infections with minocycline | |
JPH10338634A (ja) | 医薬組成物 | |
JPH07165593A (ja) | 脳機能改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20041101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050331 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050704 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060509 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060808 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060925 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070206 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070313 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070711 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070913 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080317 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110321 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130321 Year of fee payment: 5 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130321 Year of fee payment: 5 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130321 Year of fee payment: 5 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130321 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140321 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |